Dialybrid has raised EUR 15 million in a Series A round led by XGEN Venture, with participation from CDP Venture Capital’s Rilancio Fund. The financing backs clinical development of the company’s Silkothane Arteriovenous Graft, a hemodialysis vascular-access device, and supports expansion into additional vascular applications.
The underwriting logic is straightforward: vascular access remains a persistent bottleneck in dialysis care, and graft performance drives real-world outcomes. Dialybrid is now moving from preclinical promise into human clinical evidence, with fresh capital and a syndicate that mixes private life-sciences specialization with public-backed Italian venture funding.
What Dialybrid is building
Silkothane is a patented hybrid biomaterial that combines silk fibroin and polyurethane. Dialybrid is developing it as an arteriovenous graft for hemodialysis vascular access, targeting challenges faced by patients with end-stage kidney disease.
The company recently implanted Silkothane in its first human patient in Italy, marking the start of a first-in-human clinical trial. The pilot study is designed to enroll 18 adults across four Italian centers and evaluate device safety and performance, with follow-up extending up to 60 months.
Why this round matters
This deal fits a broader European medtech pattern: capital concentrates behind programs that have crossed a tangible technical milestone and can now generate clinical signals. In Dialybrid’s case, the first-in-human implantation shifts the company into a phase where execution risk is dominated by clinical delivery, study governance, and evidence quality rather than only material science.
The investor mix is also notable. The round pairs XGEN Venture’s life-sciences capital with CDP Venture Capital’s Rilancio Fund, underlining how Italian medtech is increasingly financed through blended syndicates. For founders, that can translate into longer clinical runways. For investors, it raises the bar on milestone discipline and timing, given public-backed capital’s scrutiny and reporting cadence.
Use of proceeds and key questions
Dialybrid has said the funding will support clinical development and broader preclinical vascular applications. That sets up two parallel workstreams: (1) executing the first-in-human study to produce credible safety and performance data; and (2) building a pipeline around the Silkothane platform.
Key questions for the next 12-24 months center on execution, not vision:
- Clinical pathway and endpoints: What specific performance measures will define success in the pilot, and how will results translate into a larger pivotal program?
- Center productivity and enrollment pace: Four Italian centers should help diversify investigator experience, but enrollment and protocol adherence will determine timelines.
- Manufacturing and quality systems: As the program scales, can Dialybrid lock down reproducible manufacturing, sterilization, and shelf-life performance consistent with regulatory expectations?
- Positioning versus incumbent graft options: The clinical value proposition will need to be legible to nephrologists, surgeons, and procurement teams, not only to investors.
Italy as a medtech build location
Dialybrid’s first-in-human study across four Italian clinical centers reinforces a quiet shift in European innovation. Advanced medtech development is not confined to traditional pharmaceutical hubs, and Italy’s clinical infrastructure can support early human work when teams have the right KOL network and trial operations.
For the market, the implication is less about geography and more about repeatability: if Dialybrid executes cleanly, it becomes another reference point for Italy-based device companies raising institutional rounds on the back of clinical milestones.
What to watch next
- First interim readouts from the 18-patient pilot study, including safety signals and functional performance
- Enrollment pace across the four Italian centers and any protocol amendments
- Clarity on the next clinical step after the pilot and expected regulatory path
- Evidence of manufacturing scale-up readiness and quality-system maturity
- Pipeline expansion plans for Silkothane into additional vascular indications